The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment
No Thumbnail Available
Date
2006
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Description
Bu çalışma, 26-30 Nisan 2006 tarihleri arasında Vienna[Avusturya]’da düzenlenen 41. Annual Meeting of the European-Association-for-the-Study-of-the-Liver’da bildiri olarak sunulmuştur.
Keywords
Gastroenterology & hepatology
Citation
Marcellin, P. vd. (2006). ''The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment''. Journal of hepatology, 44(Suplement 2), S275-S275.